Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOakley Regulatory News (OCI)

Share Price Information for Oakley (OCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 509.00
Bid: 506.00
Ask: 512.00
Change: 11.00 (2.20%)
Spread: 6.00 (1.186%)
Open: 503.00
High: 512.00
Low: 508.00
Prev. Close: 501.00
OCI Live PriceLast checked at -
Oakley Capital Investments is an Investment Trust

To achieve capital appreciation through investments in a diversified portfolio of private mid-market businesses primarily in Europe.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results analysis from Kepler Trust Intelligence

11 Mar 2022 09:08

RNS Number : 4996E
Oakley Capital Investments Limited
11 March 2022
 

Oakley Capital Investments (OCI)

11/03/2022

 

Results analysis from Kepler Trust Intelligence

Oakley Capital Investments (OCI) announced its final results for the year ended 31 December 2021, in which strong earnings and realisations drove significant NAV growth of 35% on a total return basis, and a share price total return of 48%.

76% of the increase in the portfolio's value was driven by earnings growth, with underlying investments maintaining their pattern of strong growth. Average EBITDA growth over the year was 28%, underpinned by digitally enabled businesses and recurring revenues.

Oakley Fund commitments at the year-end were £404m, increasing to £740m when including the initial commitment to Fund V announced post year-end. The Chairman states that "With…a rich pipeline in place, OCI has the resources to help finance new Fund investments in the coming years, using balance sheet cash as well as proceeds from anticipated future realisations".

 

Kepler View

Oakley Capital Investments (OCI) offers a concentrated, but unique exposure to a number of very interesting growth companies. Certainly, the world has changed markedly from the year end date, but the underlying themes which have driven such strong earnings growth over the last year, seem unlikely to be derailed. At the year end, the portfolio exposure to consumer companies lay at 44%, with the rest of the portfolio relatively evenly balanced between technology and education.

When compared to the LPE peer group, OCI is relatively highly committed as a proportion of NAV. However, on the same day as the results announcement, the board announced they had authorised a buyback programme up to an aggregate consideration of £20 million, potentially an indication of the value they see in the shares (currently at a c. 30% discount to NAV), and their confidence on their balance sheet position.

Oakley Capital's focus on active management and value creation has helped its tech-enabled portfolio to continue generating strong earnings growth. Its unique deal sourcing network means they are able to find promising investments at attractive valuations. In the current period of geopolitical, market and economic volatility, we share the board's confidence in Oakley's "capabilities as a leading private equity investor, as well as the long-term potential of the Oakley Funds, to continue generating superior returns for investors" which have delivered a five-year compound annual growth rate of 19%.

OCI's shares have de-rated with the market this year, and now trade at a discount to the 31/12/2021 NAV of c. 30%. One change this year is the move to quarterly NAV announcements, the first of which is expected to be announced on 27 April 2022 (for the NAV as at 31/03/2022)…

CLICK HERE TO READ THE FULL REPORT

 

Visit http://www.trustintelligence.co.uk/investor for more high quality independent investment trust research.

 

Important information

This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGCGDXXGBDGDB
Date   Source Headline
28th Jun 20247:00 amRNSOakley agrees sale of its investment in idealista
11th Jun 20247:00 amRNSOakley to invest in cybersecurity firm I-TRACING
7th Jun 20247:00 amRNSDirector Dealing
3rd Jun 20243:43 pmRNSResult of AGM
28th May 20247:00 amRNSOakley Capital invests in ProductLife Group
14th May 20247:00 amRNSOakley Capital invests in vitroconnect
8th May 20247:00 amRNSNotice of Annual General Meeting
24th Apr 20247:00 amRNSTrading Update for the 3 months ended 31 March 24
2nd Apr 20244:17 pmRNSUpdate from QuotedData
27th Mar 20247:00 amRNSDirector Dealing
27th Mar 20247:00 amRNSDirector Dealing
26th Mar 20245:46 pmRNSHolding(s) in Company
26th Mar 20245:32 pmRNSHolding(s) in Company
18th Mar 20247:00 amRNSOakley Capital invests in Horizons Optical
15th Mar 20244:00 pmRNSQuotedData's Weekly News & Interview
14th Mar 20245:32 pmRNSDividend Declaration
14th Mar 20247:00 amRNSAnnual Results 2023
4th Mar 20247:00 amRNSNotice of Results and Investor Presentation
15th Feb 20247:00 amRNSAppointment of Financial Adviser
13th Feb 20247:00 amRNSDirector Dealing
13th Feb 20247:00 amRNSDirector Dealing
24th Jan 20247:00 amRNSTrading Statement
16th Jan 20247:00 amRNSOakley agrees investment in Steer Automotive Group
15th Jan 20247:00 amRNSHolding(s) in Company
29th Dec 20237:00 amRNSSettlement of Fund I Loan
20th Dec 20239:39 amRNSUpdate from QuotedData
20th Dec 20237:00 amRNSHolding(s) in Company
28th Nov 20232:39 pmRNSResult of AGM
21st Nov 20237:00 amRNSDirector Dealing
7th Nov 20237:00 amRNSDirector Dealing
2nd Nov 20237:00 amRNSDirector Dealing
2nd Nov 20237:00 amRNSDirector Dealing
30th Oct 20237:00 amRNSNotice of AGM and Directorate Change
30th Oct 20237:00 amRNSInvestment in Alerce
26th Oct 202311:14 amRNSInvestment in Webcentral
25th Oct 20237:00 amRNSTrading update for the 3 months ended 30 Sep 2023
18th Oct 20237:00 amRNSHolding(s) in Company
18th Oct 20237:00 amRNSHolding(s) in Company
14th Sep 20235:53 pmRNSInterim Results 2023 - Replacement
14th Sep 20237:00 amRNSInterim Results for the 6 months ended 30 June 23
30th Aug 20237:00 amRNSNotice of Results and Investor Presentation
10th Aug 20237:00 amRNSOakley invests in three dental labs businesses
31st Jul 202312:14 pmRNSDirector Dealing
28th Jul 20232:27 pmRNSDirector Dealing
26th Jul 20237:00 amRNSTrading update for the 6 months ended 30 June 2023
26th Jun 20237:00 amRNSDirector Dealing
26th Jun 20237:00 amRNSDirector Dealing
19th Jun 202311:44 amRNSDirector Dealing
22nd May 202310:51 amRNSDirector Dealing
22nd May 202310:51 amRNSDirector Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.